Wayne has been consistent in saying that the company will be reimbursed $25,000 USD for each DurAVR used in trials and that there will be 900-1100 patients enrolled in the pivotal trial.
There's probably a good chance that there will be a ViV trial run concurrently, although whether it will happen in the US or not if it does take place is unknown. I'd guess 50-100 patients for the ViV trial but that's pure speculation on my part.
Ann: Capital Raise, page-90
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |